All In Biotech

Drug Trial Radar · NCT07886684

A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn

A Phase I/II First-in-human, Open-label, Multi-site Trial to Evaluate the Safety and Preliminary Efficacy of BNT3210 in Participants With Advanced Solid Tumors Known to Express Sialyl-Tn

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 173 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

173

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Oct 2029

Study completion Apr 2030

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
BioNTech (Shanghai) Pharmaceuticals Co., Ltd.
First posted
Oct 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is the first time BNT3210 will be tested in people. It will evaluate different dose levels to find suitable doses and to understand how safe the treatment is and how it may help people with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • BNT3210Drug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A only: Occurrence of dose-limiting toxicities (DLTs) during the DLT evaluation periodTime frame: Up to 21 days from the initiation of first dose of study treatment
  2. Occurrence of treatment emergent adverse events (TEAEs) by grade, seriousness, and relatednessTime frame: Up to approximately 3 years from first dose of study treatment
  3. Occurrence of dose interruptions, reductions, and discontinuation of BNT3210 due to TEAEsTime frame: Up to approximately 3 years from first dose of study treatment
  4. Part B only: Objective response rate (ORR)Time frame: Up to approximately 3 years from first dose of study treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.